2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Antibody Therapy, Natural Killer (NK) Cell Therapies, Transplantation, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Systems-Based Hematology, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, MPN, Clinical Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

1703 CBFB::MYH11 and RUNX1::RUNX1T1 acute myeloid leukemia exhibit distinct prognostic effects of remission status at allogeneic HCT: A parallel analysis of CR1 versus CR2 from the acute leukemia working party of the European society for blood and marrow transplantation

Yuhua Ru, Jia Chen Sr, MD2, Thibeault Ferhat Berland, PhD3, Raynier Devillier, PhD4, Regis Peffault De Latour, MD, PhD5, Edouard Forcade, MD, PhD6, Ibrahim Yakoub-Agha7, Anne Huynh, MD8, Igor Wolfgang Blau9, Tobias Gedde-Dahl10, Peter Pal Remenyi, MD11, Vesa Lindström12, Jan Vydra, MD, PhD13, Depei Wu Sr, MD14, Mohamad Mohty, MD, PhD15, Norbert Claude Gorin, MD, PhD16, Jordi Esteve, MD, PhD17, Jaime Sanz, MD, PhD18, Arnon Nagler I, MD19, Eolia Brissot, MD, PhD20
1 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China
2 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China
3 EBMT Paris Office, Hôpital Saint-Antoine, AP-HP, Sorbonne University,, Paris, France
4 Institut Paoli-Calmettes, Aix-Marseille Université, Marseille, France, Marseille, France
5 Saint-Louis Hospital, BMT unit, AP-HP, Université Paris Cité, Paris, France
6 CHU Bordeaux, Hôpital Haut-Lévêque, Pessac, France
7 CHU de Lille, Uni Lille, INSERM U1286, Infinite, Lille, France
8 Institut Universitaire du Cancer de Toulouse-Oncopole, CHU de Toulouse, Toulouse, France
9 Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, Berlin, Germany
10 Oslo University Hospital, and Institute of Clinical Medicine, University of Oslo, Oslo, Norway
11 South-Pest Central Hospital, National Institute of Hematology and Infectious Diseases, Budapest, Hungary
12 Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland
13 Institute of Hematology and Blood Transfusion, Prague, Czech Republic
14 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China
15 EBMT Paris Office, Hôpital Saint-Antoine, AP-HP, Sorbonne University,, Paris, France
16 EBMT Paris Office, Hôpital Saint-Antoine, AP-HP, Sorbonne University,, Paris, France
17 Clínic de Barcelona, Barcelona, Spain
18 Hospital Universitari i Politècnic La Fe, Valencia, Spain
19 Chaim Sheba Medical Center, Tel Hashomer, and Tel Aviv University, Tel Aviv, Israel
20 EBMT Paris Office, Hôpital Saint-Antoine, AP-HP, Sorbonne University,, Paris, France

 Introduction

Core-binding factor (CBF) acute myeloid leukemia (AML) comprises two molecularly distinct entities, CBFB::MYH11 AML and RUNX1::RUNX1T1 AML. Although both are traditionally classified as favorable-risk AML, accumulating evidence suggests that the two molecular subtypes differ in disease biology, treatment response, and prognosis. Allogeneic hematopoietic cell transplantation (allo-HCT) is not routinely recommended in first complete remission (CR1) for CBF-AML and is more commonly considered after relapse in patients who achieve second complete remission (CR2). Whether a uniform strategy regarding transplant timing is appropriate for both molecular subtypes remains uncertain. Therefore, we compared outcomes after allo-HCT in CR1 versus CR2 separately for each molecular subtype.

 

Methods

We retrospectively analyzed two cohorts of adults aged ≥18 years with AML harboring CBFB::MYH11 or RUNX1::RUNX1T1 who underwent their first allo-HCT in CR1 or CR2 between 2010 and 2023. Multivariable analyses were performed separately within each molecular subtype. Data were reported to the European Society for Blood and Marrow Transplantation (EBMT) registry.

 

Results

The two cohorts included a total of 3,899 patients. The CBFB::MYH11 cohort comprised 1,292 patients, with 643 undergoing allo-HCT in CR1 and 649 in CR2. The RUNX1::RUNX1T1 cohort comprised 2,607 patients, with 2,137 undergoing allo-HCT in CR1 and 470 in CR2. Median follow-up in CR1 and CR2 was 4.0 and 4.4 years, respectively, for CBFB::MYH11 AML and 3.0 and 3.9 years, respectively, for RUNX1::RUNX1T1 AML.

 

In CBFB::MYH11 AML, the 2-year overall survival (OS) was 80.1% in CR1 and 76.8% in CR2. Leukemia-free survival (LFS) was 70.8% and 67.3%, graft-versus-host disease (GVHD)-free, relapse-free survival (GRFS) was 57.1% and 50.9%, relapse incidence (RI) was 17.6% in both groups, and non-relapse mortality (NRM) was 11.6% and 15.1%, respectively. In CR1 and CR2, the 180-day cumulative incidences of grade II–IV acute GVHD (aGVHD) were 29.1% and 26.5%, and cumulative incidences of grade III–IV aGVHD were 10.6% and 11.4%, respectively. The 2-year cumulative incidences of chronic GVHD (cGVHD) were 36.1% and 37.9%, and cumulative incidences of extensive cGVHD were 9.5% and 12.3%, respectively.

 

In multivariable analysis, no significant differences between CR1 and CR2 were observed for OS (hazard ratio [HR], 1.00; P=0.997), LFS (HR, 1.05; P=0.658), GRFS (HR, 1.11; P=0.298), RI (HR, 1.03; P=0.843), NRM (HR, 1.08; P=0.638), grade II–IV aGVHD (HR, 0.89; P=0.370), grade III–IV aGVHD (HR, 0.96; P=0.814), cGVHD (HR, 1.00; P=0.978), or extensive cGVHD (HR, 0.96; P=0.854).

 

In RUNX1::RUNX1T1 AML, the 2-year OS was 72.5% in CR1 and 60.1% in CR2. LFS was 64.2% and 52.4%, GRFS was 53.9% and 40.3%, RI was 22.1% and 26.2%, and NRM was 13.7% and 21.4%, respectively. In CR1 and CR2, the 180-day cumulative incidences of grade II–IV aGVHD were 29.2% and 28.9%, and cumulative incidences of grade III–IV aGVHD were 9.4% and 11.2%, respectively. The 2-year cumulative incidences of cGVHD were 35.5% and 32.0%, and cumulative incidences of extensive cGVHD were 7.0% and 9.3%, respectively.

 

In multivariable analysis, allo-HCT in CR2 was associated with inferior OS (HR, 1.40; P<0.001), inferior LFS (HR, 1.30; P=0.003), inferior GRFS (HR, 1.40; P<0.001), and higher NRM (HR, 1.39; P=0.018), while RI was not significantly different (HR, 1.23; P=0.075). No significant differences were observed in grade II–IV aGVHD (HR, 1.05; P=0.648), or cGVHD (HR, 1.12; P=0.291). CR2 was associated with a higher risk of grade III–IV aGVHD (HR, 1.45; P=0.042) and extensive cGVHD (HR, 1.64; P=0.022).

 

Conclusion

Outcomes after allo-HCT in CR1 and CR2 were comparable in patients with CBFB::MYH11 AML, whereas in patients with RUNX1::RUNX1T1 AML, allo-HCT in CR2 was associated with inferior OS, LFS, and GRFS and higher NRM. These findings support a molecular subtype-specific approach to transplant timing for CBFB::MYH11 and RUNX1::RUNX1T1 AML.

Yuhua Ru: No relevant conflicts of interest to declare.